12390 EL CAMINO REAL, SAN DIEGO, CA
Departure of Cortney Caudill as COO at Halozyme Therapeutics
REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Annual Meeting of Stockholders Held; Three Proposals Voted On
Appoints Darren Snellgrove as Chief Financial Officer
Bylaw Amendments - Halozyme Therapeutics Revises Director Removal Policy
Annual Report to Security Holders
Appoints David Ramsay as Interim Chief Financial Officer
Financial Results, Press Release
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence
Amended Tender Offer Statement by Third Party